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Background: Inﬂiximab revolutionized the treatment paradigm of Crohn’s disease (CD), but did not
reduce the need for surgery. The impact of biologic agents on surgical complication rates remains
debated. The aim of this study was to determine the effect of preoperative inﬂiximab use on early
postoperative complications in patients with CD undergoing abdominal surgery.
Method: PubMed and Embase databases were searched to identify comparative studies that investigated
postsurgical morbidity in CD patients receiving inﬂiximab preoperatively with those not on inﬂiximab.
We used meta-analysis with random-effects model to calculate the pooled odds ratios (ORs) with 95%
conﬁdence intervals (CIs) for total complication rate as well as major, minor, infectious, and non-
infectious complications.
Results: A total of 18 studies involving 5769 patients included in this systematic review. There was
signiﬁcant association between inﬂiximab therapy prior to surgery and total (OR ¼ 1.45, 95% CI 1.04
e2.02; 13 studies, 2538 patients), infectious (OR ¼ 1.47, 95% CI 1.08e1.99; 10 studies, 2116 patients) and
non-infectious (OR ¼ 2.29, 95% CI 1.14e4.61; 3 studies, 729 patients) postoperative complications
respectively. There was no signiﬁcant disparity in the major (OR ¼ 1.39, 95% CI 0.85e2.27; 9 studies, 3696
patients) and minor (OR ¼ 1.39, 95% CI 0.57e3.40; 5 studies, 753 patients) complication rates between
inﬂiximab and control groups. No publication bias was detected.
Conclusion: Preoperative inﬂiximab use modestly increases the risk of total early postoperative com-
plications, and particularly infectious complications in CD patients.
 2013 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Introduction
Inﬂiximab, a chimeric anti-tumor necrosis factor alpha (anti-
TNF-a) antibody, revolutionized the therapeutic regime of Crohn’s
disease (CD).1 However, evidences from population-based survey
showed that the introduction of inﬂiximab since 1998 did not alter
the natural history of the disease, and neither reduced the need for
surgery.2 At least 50% of patients will require surgical treatment in
the ﬁrst ten years of disease and approximately 70e80%will require
surgery during their lifetime.1,2
The immunosuppressive effects of inﬂiximab may induce pa-
tients at an increased risk of infection.3 Moreover, surgery itself
causes a complex stress on the human body that leads to some
reduction of cell mediated immunity.4 Therefore, the impact of bio-
logic agents on surgical complication rates becomes amajor concern
in clinical practice. Previous observational studies evaluating the: þ86 29 82539041.
Fan).
ciates Ltd. Published by Elsevier Ltassociation between preoperative therapy of inﬂiximab and post-
operative complications resulted in inconsistent outcomes. Even two
previous meta-analyses in an attempt to answer this question pro-
duced contrary conclusions.5,6 Kopylov et al. found that preoperative
inﬂiximab treatment is associated with an increased risk of post-
operative infectious complications, and with a trend toward an
increased risk of non-infectious and total complications.5 Whereas
the pooled results by Rosenfeld et al. demonstrated no signiﬁcant
disparity in the major complication, minor complication, reopera-
tion, and 30-day mortality rates between inﬂiximab and control
groups. So they considered that inﬂiximabmay be safe to continue in
the preoperative period without increasing the risk of postoperative
complications for CD patients.6
The purpose of our study was to perform a comprehensive
systematic review of the existing literature to evaluate the effect of
preoperative inﬂiximab use on early postoperative complications in
patients with CD undergoing abdominal surgery. We would
determine the nature of these complications if inﬂiximab treat-
ment in the preoperative period increased the overall complication
rate.d. All rights reserved.
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2.1. Search strategy
Potentially relevant studies were identiﬁed by searching the
electronic databases including PubMed and Embase. Reference lists
from all available review articles and primary studies were hand-
searched to identify additional relevant publications. The search
terms contained ‘(inﬂiximab or tumor necrosis factor or TNF) and
(postoperative or post-operative or surgical complications) and
(inﬂammatory bowel disease or Crohn’s disease)’. We performed
the ﬁnal search on 17 May, 2013.
2.2. Study selection
Two reviewers (Z.Y. and L.H.) independently evaluated all of the
retrieved studies according to pre-speciﬁed selection criteria. Dis-
crepancies were resolved by consensus or with the consultation of a
third reviewer (D.F.). There was no language restriction. The
following eligibility criteria was applied: (1) population: patients
with CD undergoing abdominal surgery; (2) intervention: inﬂix-
imab treatment prior to surgery; (3) comparator: controls not
receiving inﬂiximab preoperatively; (4) outcomes: short-term
complications either reported as total, major, minor, infectious or
non-infectious, or listed individually to allow classiﬁcation by the
reviewers. We summarized a list of the deﬁnition of major, minor,
infectious and non-infectious complications in each study in
Supplemental Table 1.
Studies were excluded if they did any of the following: (1)
reported duplicate results that were published in other articles;
only the most recent and complete data were included in the
systematic review. (2) studies that included CD and ulcerative
colitis (UC) patients as one group; we tried to contact the corre-
sponding authors to obtain the data in their CD patients
separately.
2.3. Data extraction and quality assessment
Two reviewers (Z.Y. and Q.W.) independently extracted the data
using a pre-deﬁned form (Supplemental Table 2) and then crossFig. 1. Study ﬂochecked the extracted data. We collected information on the
following items: ﬁrst author and year of publication, country of
origin, study period, type of publication, duration of inﬂiximab
exposure, duration of complications after surgery, number of pa-
tients, demographic characteristics (sex, age at surgery, body mass
index, smoking status), disease characteristics (duration, severity,
concomitant medications) and surgical characteristics (indication,
proportion of previous surgery and emergency, type and approach
of operation). The quality of the study reports was evaluated using
the Newcastle-Ottawa scale (NOS), a method for assessing the
quality of nonrandomised studies in meta-analysis.7 The scales
allocate stars, maximum of nine, for quality of selection, compa-
rability, exposure and outcome of study participants. We consid-
ered studies with a score of 7 or above as high quality.
2.4. Statistical analysis
Pooled odds ratios (ORs) and 95% conﬁdence intervals (CIs) were
generated using a random-effects model that considered both
within and between-study variations. The c2-based Q-test and the
I2 statistic were used to evaluate statistical heterogeneity. Specif-
ically, a Q statistic of P < 0.10 or I2 > 50% indicated signiﬁcant
heterogeneity among studies. To detect and evaluate clinical het-
erogeneity, we performed sensitivity analysis without the less-
qualiﬁed studies or the study, which has shown the most signiﬁ-
cant difference accordingly.We plotted Begg’s funnel plot to test for
publication bias. We also used Egger’s weighted regression method
to calculate the P value for bias. All analyses listed above were
conducted using the software Stata (Version 12.0; Stata Corpora-
tion, College Station, TX, USA).
3. Results
3.1. Search results
The initial search identiﬁed 2332 potentially relevant citations,
of which 2289 were discarded after title and abstract screening. A
total of 43 citations were retrieved for detailed evaluation. Eight
meeting abstracts duplicated with the corresponding full-text ar-
ticles published subsequently. Thirteen studies were excluded forw diagram.
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ORIGINAL RESEARCHaddressing data on UC population alone. Additional four studies did
not distinguish CD patients from a mixed cohort of inﬂammatory
bowel disease (IBD) patients,8e11 although we contacted these
corresponding authors. Finally, 18 observational studies with 5769
patients (median: 210.5; range: 76e2293) published from 2002 to
2013 were included in this systematic review (Fig. 1).12e29 Total
complication rates could be assessed in 13 of these studies.14e
23,25,27,29 Major, minor, infectious and non-infectious complica-
tions were assessed in nine,12e14,16,20,22,23,26,28 ﬁve,12,14,16,22,23
ten,13e16,18,20,22,27e29 and three studies respectively.16,22,27
3.2. Study and patient characteristics
The characteristics of studies and patients are shown in
Supplemental Table 2. Eleven studies were performed in the UnitedFig. 2. Pooled outcome for development of total complications in patients exStates, ﬁve in Europe, one in Japan, and one in Brazil. Fourteen
studies published as full-text articles, while the other four as ab-
stracts. In all, 1116 out of 5769 (19.3%) patients included in our sys-
tematic review received inﬂiximab and 4653 (80.7%) did not. Five
studies included a minority of patients treated with adalimumab
and certolizumab pegol (196/1116, 17.6%).19,21,24,26,28 Inﬂiximabwas
given within 12 weeks prior to surgery in eight studies,16,20,22e27 8
weeks in three studies,13,17,28 8 weeks before surgery or 4 weeks
after it in three studies,12,15,19 and 4 weeks in one study.21 The
duration of follow-up was reported at 30 days in 13 studies,13,15e
17,19e21,23e28 and at 10 days in one study,14 and without available
information in four studies.12,18,22,29 Only 4 out of 18 studies were
considered as high-quality ones based on the NOS.14,22,24,28
Therewere 2156 (42.8%) males from the available data about the
sex in 14 studies.13e17,19e26,28 Data on the proportion of emergentposed to IFX preoperatively vs. controls: A. Forest plots; B. Funnel plots.
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ORIGINAL RESEARCHsurgery were available in eight studies including 2015 pa-
tients,13,15,17,19,20,24,25,28 of whom 289 (14.3%) underwent urgent
operation. The type of surgery among the studies was quite
different. Some studies included patients undergoing only one
speciﬁc type of surgery, whereas some others included patients
undergoing any intestinal surgery. Data on the surgical approach
were available in 11 studies including 2417 patients,13,15e
20,22,25,27,28 of whom 953 (39.4%) underwent laparoscopic opera-
tion. We could not conduct subgroup analyses for speciﬁc oper-
ative interventions due to the variability of surgical parameters
included in the studies.
Data on concomitant medications, stratiﬁed by inﬂiximab
treatment, were available in 10 studies.13,14,16,17,19,22e24,26,28 Cor-
ticosteroids were equi-frequently used between inﬂiximab and
non-inﬂiximab groups (OR ¼ 1.10, 95% CI 0.92-1.31, 10 studies,
4274 patients). Patients in the inﬂiximab group had a more
frequent use of immunomodulators (azathioprine and metho-
trexate) (OR ¼ 1.70, 95% CI 1.34e2.16, 5 studies, 1613 patients).
3.3. Total complications
There were a total of 2538 patients (663 in the inﬂiximab group
and 1875 in the control group) in 13 studies reporting total com-
plications after operation in CD patients receiving inﬂiximab pre-
operatively. The summary OR was 1.45 (95% CI 1.04e2.02;
Pheterogeneity ¼ 0.01, I2 ¼ 57.7%), indicating a signiﬁcantly increased
risk, but with signiﬁcant heterogeneity among studies (Fig. 2A).
Whenwe excluded the studies published as abstracts or the studies
with some patients treated with other anti-TNF-a agents, the in-
crease in total complications remained statistically signiﬁcant.
Whenwe limited to the studieswith inﬂiximabuse in12weeksprior
to surgery or the studies with reporting complications for 30 post-
operative days, a trend towards increased risk was observed but
without statistical signiﬁcance (Table 1). No publication bias was
detected according to the symmetry of the funnel plot and the
Egger’s P-value (Fig. 2B).
3.4. Major and minor complications
When the complications were divided into major and minor
ones, nine studies that reported major complications included 653
patients who received inﬂiximab preoperatively and 3043 controls,
and ﬁve studies that reported minor complications included 202
patients who received inﬂiximab preoperatively and 551 controls.
The summary OR for major complications was 1.39 (95% CI 0.85e
2.27; Pheterogeneity < 0.01, I2 ¼ 71.5%), suggesting that there was no
association between preoperative inﬂiximab use and major com-
plications, but a signiﬁcant heterogeneity among studies (Fig. 3A).
The summary OR for minor complications was 1.39 (95% CI 0.57e
3.40; Pheterogeneity ¼ 0.07, I2 ¼ 53.5%), also indicating no association
but a signiﬁcant heterogeneity among studies (Fig. 3C). Similar re-
sults were obtained in the sensitivity analyses (Table 1). Only when
we limited to the studieswith full-textor the studieswith inﬂiximab
use in 12 weeks prior to surgery, a signiﬁcant increase in minor
complications was observed. No publication bias was detected on
the basis of the symmetry of the funnel plot and the Egger’s P-value
(Fig. 3B and D).
3.5. Infectious and non-infectious complications
When the complications were grouped into infectious and
non-infectious ones, ten studies that reported infectious compli-
cations included 626 patients who received inﬂiximab preopera-
tively and 1490 controls, and three studies that reported non-
infectious complications included 171 patients who received
Fig. 3. Pooled outcome for development of major and minor complications in patients exposed to IFX preoperatively vs. controls: A. Forest plots for major complications; B. Funnel
plots for major complications; C. Forest plots for minor complications; D. Funnel plots for minor complications.
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infectious complications was 1.47 (95% CI 1.08-1.99;
Pheterogeneity ¼ 0.14, I2 ¼ 33.9%), indicating a signiﬁcantly increased
risk (Fig. 4A). The summary OR for non-infectious complicationsFig. 4. Pooled outcome for development of infectious and non-infectious complications
complications; B. Funnel plots for infectious complications; C. Forest plots for non-infectiouwas 2.29 (95% CI 1.14e4.61; Pheterogeneity ¼ 0.12, I2 ¼ 52.5%), sug-
gesting a signiﬁcantly increased risk, but with a little heterogeneity
among studies (Fig. 4C). Similar results were obtained in the
sensitivity analyses (Table 1). Only when we limited to the studiesin patients exposed to IFX preoperatively vs. controls: A. Forest plots for infectious
s complications; D. Funnel plots for non-infectious complications.
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no association between preoperative inﬂiximab use and non-
infectious complications, with a signiﬁcant heterogeneity among
studies. No publication bias was detected on the basis of the sym-
metry of the funnel plot and the Egger’s P-value (Fig. 4B and D).
4. Discussion
This systematic review displayed that preoperative treatment of
inﬂiximab was associated with a small but statistically signiﬁcant
increase in total complication rate following abdominal surgery for
CD patients. The major source of these complications was the
postoperative infection, although the non-infectious complications
were also increased in the pooled result of the three included
studies.
Our systematic review differed from the previous evaluations in
several respects.5,6 The ﬁrst difference was the inclusion of recently
published articles. We conducted an exhaustive literature search
and included several additional recent studies with large numbers
of target patients (>100) who received inﬂiximab preoperatively.
Second, although we found an increased risk of total postoperative
complications, there was high degree of statistical heterogeneity
between studies. We did sensitivity analyses limited to several
speciﬁc subgroups to examine the robustness of our results with
respect to the choice of study method and other confounding fac-
tors. Third, we used two classiﬁcations to determine the nature of
the complications. There was no association between preoperative
inﬂiximab use and postoperative outcomes in either major or mi-
nor complications, and with high heterogeneity among studies.
However, the pooled outcome on increased risk of infectious
postoperative complications was substantial in statistics. Thus it
will be more appropriate to sort the complications as infectious and
non-infectious in future studies.
Our previous meta-analysis focusing on the similar topic in UC
patients summarized the postsurgical outcomes affected by pre-
operative therapy of inﬂiximab from 13 observational studies.30 In
contrast to the results of this systematic review, inﬂiximab use in
the preoperative period was not associated with an increase in
total, infectious, and non-infectious complications in patients with
UC undergoing abdominal surgery. It illustrated to some extent that
CD and UC are quite different in terms of medical and surgical
management.1 Surgery does not cure CD, and up to 40% of patients
will eventually need secondary operation.2 The postsurgical mor-
bidities for CD patients may be different from UC due to the larger
number of surgeries and more aggressive medications in order to
minimize the impact of disease. Therefore, the two recent meta-
analyses combining CD and UC as a whole to deal with this issue
might be inappropriate and unpractical, although they performed
subgroup analyses for CD and UC patients separately.31,32
Similar to other meta-analyses in this ﬁeld, the current sys-
tematic review has several limitations. First, given the nature of all
included studies were retrospective, the major limitation of these
studies was the incomparability between inﬂiximab and control
groups. The primary objective in a few studies was not limited to
inﬂiximab-treated versus untreated patients. Only four studies
received high points on the NOS score. Secondly, there was high
degree of heterogeneity among the included studies in the syn-
theses, which might stem from the various inclusion criteria and
nonuniform deﬁnitions of the complications (Supplemental
Table 1). In addition, although we conducted sensitivity analyses
to discern the inﬂuence of the timing of the last preoperative
inﬂiximab on the rate of complications and the timing of the
assessment of complications, it was impossible to stratify the meta-
analysis results for some other important confounders with respect
to disease-related and surgery-related parameters as a result ofinsufﬁcient data and nonuniform presentations (Supplemental
Table 2). Thirdly, patients treated with inﬂiximab were more
likely to be treated with immunomodulators (OR ¼ 1.70, 95% CI
1.34e2.16), indicating that they suffered from more aggressive
disease condition than patients who did not receive preoperative
anti-TNF-a therapy. These patients usually had additional risk fac-
tors for adverse surgical outcomes such as malnutrition, anemia,
ﬁstulae, past surgeries, and urgent indications for operation.
In conclusion, preoperative inﬂiximab use slightly increases the
incidence of total early postoperative complications, and particu-
larly infectious complications in CD patients. The surgical inter-
vention for CD patients should be considered according to the
immunosuppressive therapy prior to surgery. However, these re-
sults need to be interpreted with caution due to the study limita-
tions. Future prospective studies controlling potential confounding
variables and using homogenous classiﬁcation of postoperative
complications are urgently seeking to conﬁrm our ﬁndings.
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